Technical Bulletins

19 bulletins:

Human Papilloma virus, High Risk Only; Oral/Anal/other non-cervical specimens

About 75 percent of sexually active people will be infected with HPV during their lifetime. Human papilloma viruses are a group of more than 100 different viruses. Several high risk types of HPV have been associated with a variety of cancers including oral, anal, and penile cancers. This assay detects only these high risk HPV types. This is a screening test to be used along with cytology to help identify patients who have HPV positive lesions at high risk for certain cancers

Automated Fecal Occult Blood Test

Submit a single random sample from one stool specimen collected in FOBT Sample Collection Device. (stool specimen should coat the ridges of the probe in sample bottle)

Prothrombin Gene Mutation (also known as Factor II)

Effective January 1, 2005, the volume of whole blood necessary for the performance of Prothrombin Gene Mutation testing is reduced to a minimum of 0.5 mL of whole blood in an EDTA tube. Volumes less than 0.5 mL may lead to failed isolations due to the dilution of the blood with anticoagulants.

Hereditary Hemochromatosis

Effective January 1, 2005, the volume of whole blood necessary for the performance of HHDNA testing is reduced to a minimum of 0.5 mL of whole blood in an EDTA tube. Volumes less than 0.5 mL may lead to failed isolations due to the dilution of the blood with anticoagulants.

Her-2/neu gene amplification, FISH

Used as a prognostic factor in stage II, node-positive breast cancer patients. An aid to predict disease-free and overall survival of the above patients when treated with cyclophosphamide, doxorubicin and 5-fluorouracil. Breast cancer patients with a 2+ IHC Her-2/neu stain who are candidates for Herceptin treatment.

BCR/ABL, Translocation 9;22, Fluorescence in situ Hybridization (FISH), Philadelphia chromosome.

Allergy Testing

Testing for Total IgE and Allergen Specific IgE levels on serum samples will be performed at the NorDx Scarborough campus laboratory. This change transfers the status of these tests to �in-house� procedures.

Cystic Fibrosis Carrier Screening and Genotyping

Testing for Cystic Fibrosis Carrier Screening and Genotyping will be performed using the Hologic invader platform. This assay detects 46 mutations and polymorphisms in the CFTR gene, including the 23 mutations on the ACMG recommended panel plus 23 additional variants.

Cystic Fibrosis Informed Consent Form

A completed Cystic Fibrosis Informed Consent Form is required with each CF specimen.